AAV - CNGB3
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achromatopsia
Conditions
Achromatopsia
Trial Timeline
Jan 16, 2017 → Oct 25, 2019
NCT ID
NCT03001310About AAV - CNGB3
AAV - CNGB3 is a phase 1/2 stage product being developed by MeiraGTx for Achromatopsia. The current trial status is completed. This product is registered under clinical trial identifier NCT03001310. Target conditions include Achromatopsia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03001310 | Phase 1/2 | Completed |
Competing Products
2 competing products in Achromatopsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| adeno-associated virus vector AAV- CNGA3 | MeiraGTx | Phase 1/2 | 33 |
| Prior exposure to AAV-CNGA3 or AAV-CNGB3 | MeiraGTx | Pre-clinical | 15 |
Other Products from MeiraGTx
AAV RPE65Phase 1/2
33
adeno-associated virus vector AAV- CNGA3Phase 1/2
33
AAV2hAQP1Phase 1
25
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)Phase 1
25
AAV OPTIRPE65Pre-clinical
15